|
|
|
|
|
|
|
|
|
|
|
|
|
Evaluating The Impact Of In-House Testing Strategies
|
|
Article | By Kaden Moore, August Bioservices
|
Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients.
|
|
|
|
|
|
Building Late-Stage Efficiency Into Biologics Development
|
|
White Paper | By Justyna Adamczyk, Rezon Bio
|
Building late-stage efficiency early in biologics development prevents scale-up delays. Flexible platforms and risk-based validation streamline technology transfer and lower production costs.
|
|
|
|
|
|
The Challenges Of Moving A Bioconjugate From Clinic To Market
|
|
Article | By Iwan Bertholjotti and Dr. Bernhard Stump, Lonza
|
Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them.
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
“RNA-based therapeutics” is now a diverse and wide field of application; outsourcing the components of these programs is challenging. Executives at the Society For RNA Therapeutics (SRT) say assembling an entire supply chain can soak up time and resources. Which partners to select depends on what area of RNA development you are pursuing. A fundamental task before all RNA sponsors is thinking deeply in terms of assembling development and manufacturing ecosystems, starting at the earliest stages of research and company formation.
|
|
|
|
|
|
Globalization vs. Localization: Where To Outsource In A Changing World
|
|
By Outsourced Pharma
|
Geographical strategy for outsourcing is a pressing issue: balancing historical global supply chains with current pressures to reshore/nearshore parts of operations. In this fireside chat, editorial board members Lynn Cinelli, and Kent Pryor help us navigate the geographical pressures of modern outsourcing, the root causes of global supply chain breakdowns, the hardest assets to move across regions, and whether time-sensitive sponsors should simplify their chain or hunt for best-in-class partners globally.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
Strategic Approaches On The Path To GMP Manufacture
|
|
Q&A | Avid Bioservices
|
Tech transfer is a critical opportunity to establish a strategy for process performance qualification, mitigate late-stage obstacles, and streamline the pathway to clinical and commercial production.
|
|
|
|
|
|
|
|
|
|
Nitrosamine Risk: Detection And Control
|
|
Webinar | Pace® Life Sciences
|
Bioprocess control relies on clear insight into cell health. Automated tracking cuts risk, saves time, boosts yield, and helps scale up fast to ensure smooth, top quality batch production runs daily.
|
|
|
|
|
|
|
|
Early-Phase Injectable Formulation Development
|
|
White Paper | Thermo Fisher Scientific
|
Discover how expert-driven strategies and data-centric tools can help you overcome formulation challenges and accelerate the development of stable, high-performance injectable therapeutics.
|
|
|
|
|
|
Maximizing Efficiency In mAb Manufacturing
|
|
Article | By Daniel Pirsch, Nicole Kavanaugh, and Michael Buckley, Catalent
|
Get access to the tools and expertise needed to support process development for biologic therapies from the clinical trial phase to commercialization.
|
|
|
|
|
|
|
|
|
|
Lentiviral Vector Upstream Process
|
|
Application Note | Cytiva
|
Lentiviral vector production is moving beyond adherent systems. Assimilate how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
|
|
|
|
|
|
Applying Vaccine Expertise To Cell And Gene Therapy
|
|
Article | IDT Biologika
|
Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of CGT development and production.
|
|
|
|
|
|
The Single-CDMO Advantage For Biologics
|
|
White Paper | Curia
|
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
|
|
|
|
|
|
|
|
|
|
|
|
Outsourced Pharma Capabilities Update - ADCs
|
This digital event focuses on antibody-drug conjugates (ADCs) and how CDMOs support their development from early stages through clinical and commercial manufacturing. It highlights the importance of selecting the right partner for these complex therapies, including expertise in conjugation processes, scalability, regulatory needs, and integrated development services. Attendees will learn key criteria for evaluating CDMOs and how to align partnerships to accelerate ADC program success. Click here to learn more.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
